SCHEMBL1357985

SCHEMBL1357985

NC1CSC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL14722960 0.95
Bromide SCHEMBL324722 0.95
SCHEMBL7203154 0.79
SCHEMBL11940925 0.76
SCHEMBL2860312 0.76
SCHEMBL13476029 0.76
SCHEMBL10035838 0.73
Hydrochloric Acid SCHEMBL10708970 0.73
SCHEMBL13308377 0.71
SCHEMBL5803958 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4743078-A2 APOL1 INHIBITORS AND METHODS OF USE Maze Therapeutics, Inc. (US) 2026-05-20 EP disclosed
EP-4743079-A2 APOL1 INHIBITORS AND METHODS OF USE THEREOF Maze Therapeutics, Inc. (US) 2026-05-20 EP disclosed
US-20250361273-A1 METHODS AND COMPOSITIONS FLAGSHIP PIONEERING INNOVATIONS VII, LLC 2025-11-27 US disclosed
US-20250092054-A1 FUSED PYRIDINES FOR CONTROLLING INVERTEBRATE PESTS FMC CORPORATION 2025-03-20 US disclosed
WO-2025015106-A2 APOL1 INHIBITORS AND METHODS OF USE THEREOF MAZE THERAPEUTICS, INC. (US) 2025-01-16 WO disclosed
WO-2025015104-A2 APOL1 INHIBITORS AND METHODS OF USE MAZE THERAPEUTICS, INC. (US) 2025-01-16 WO disclosed
US-12103915-B2 TEAD inhibitors and methods of uses thereof INSILICO MEDICINE IP LIMITED (HK) 2024-10-01 US disclosed
US-20240166608-A1 TEAD INHIBITORS AND METHODS OF USES THEREOF INSILICO MEDICINE IP LIMITED (HK) 2024-05-23 US disclosed
EP-4347587-A1 FUSED PYRIDINES FOR CONTROLLING INVERTEBRATE PESTS FMC Corporation (US) 2024-04-10 EP disclosed
EP-4313295-A1 PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) Almac Discovery Limited (GB) 2024-02-07 EP disclosed
WO-2007080131-A2 ANTHRANILAMIDE DERIVATIVES AND THEIR USE FOR THE CONTROL OF INSECTS AND ACARI SYNGENTA PARTICIPATIONS AG (CH) 2007-07-19 WO disclosed
WO-2007046548-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-04-26 WO disclosed
WO-2003054037-A1 COMPLEXES BASED ON HETERO-CYCLOBUTENYL LIGANDS EQUISTAR CHEMICALS, LP (US) 2003-07-03 WO disclosed
US-6586545-B1 Olefin polymerization catalyst, activator and complex of metal and heterocyclobetenyl ligand EQUISTAR CHEMICALS, LP 2003-07-01 US disclosed
EP-0811012-A1 METHOD OF PRODUCING L-ASPARTYL-D-ALANINE-N-(THIETHANE-3-YL)-AMIDES Degussa Aktiengesellschaft (DE) 1997-12-10 EP disclosed
WO-1996026213-A1 METHOD OF PRODUCING L-ASPARTYL-D-ALANINE-N-(THIETHANE-3-YL)-AMIDES DEGUSSA AKTIENGESELLSCHAFT (DE) 1996-08-29 WO disclosed
US-5407932-A Bactericides WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) 1995-04-18 US disclosed
EP-0393400-B1 Novel quinolone derivatives, preparation processes thereof, and antibacterial agents containing the same WAKUNAGA SEIYAKU KK (JP) 1994-12-21 EP disclosed
US-5245037-A Synthetic bactericides WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) 1993-09-14 US disclosed
EP-0393400-A1 Novel quinolone derivatives, preparation processes thereof, and antibacterial agents containing the same WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) 1990-10-24 EP disclosed